Introduction
============

*Streptoccocus pneumoniae*pneumonia remains associated with high morbidity and mortality. Antibiotic treatment frequently is insufficient in limiting lung damage due to inflammation. Therefore, additional treatment strategies are needed. The drug r-roscovitine, a cyclin-dependent kinase (CDK) inhibitor, was demonstrated to reduce inflammation in several models of inflammation.

Objective
=========

We studied the potential of r-roscovitine to modulate host defense during sterile inflammation and bacterial infection of the lung.

Methods
=======

Isolated neutrophils were treated with 20 μM r-roscovitine and CDK and caspase 3 activity were determined by western blot analysis. Sterile lung inflammation was induced by intranasal administration of 100 μg lipoteichoic acid (LTA), a prominent cell wall component of Gram-positive bacteria. Simultaneously 70 mg/kg r-roscovitine or vehicle was injected intraperitoneally. Twenty-four hours later bronchoalveolar lavage (BAL) was performed and differential cell counts were determined. Bacterial pneumonia was induced by inoculation of 5 × 10^4^CFU *S. pneumoniae*. r-roscovitine (70 mg/kg) or vehicle was administered 24 hours later in combination with antibiotic therapy (ceftriaxon; 20 mg/kg). Mice were sacrificed after 48 hours. In a second experiment, mice were infected and treated at 24 and 72 hours and sacrificed 96 hours post infection.

Results
=======

r-roscovitine treatment significantly reduced phosphorylated CDK substrate and increased cleaved caspase 3 levels in isolated neutrophils. During LTA-induced lung inflammation, r-roscovitine treatment significantly reduced the amount of PMNs in the BAL fluid and cytokines in lung homogenates. After 48 hours of bacterial pneumonia, r-roscovitine-treated animals displayed enhanced pulmonary bacterial outgrowth. Cytokine production and lung damage scores were higher in the r-roscovitine-treated group as compared with vehicle. Interestingly, when studying the animals at 96 hours post infection, r-roscovitine treatment resulted in lower bacterial outgrowth and chemokine levels in the lung.

Conclusion
==========

With this study, we reproduced earlier findings that r-roscovitine treatment reduces CDK activity and induces apoptosis in neutrophils; we demonstrated that r-roscovitine diminishes inflammatory responses in sterile inflammation; and we found that r-roscovitine treatment in bacterial pneumonia is detrimental early in infection but beneficial at later time points. We believe that the negative effect of r-roscovitine reflects the importance of neutrophil antibacterial defense early in infection. Yet, during resolution of infection, apoptosis of neutrophils induced by r-roscovitine could present a way of damage control as opposed to unwanted side effects of neutrophil function.
